Pharm
Prasugrel
search
Prasugrel
, Effient
See Also
Platelet ADP Receptor Antagonist
Antiplatelet Therapy for Vascular Disease
Clopidogrel
Ticagrelor
Indications
Prevention of Thrombotic Events
See
Platelet ADP Receptor Antagonist
See
Antiplatelet Therapy for Vascular Disease
Prevention of thrombotic events following PCI with coronary stenting
Contraindications
Active Bleeding
Increased bleeding risk (Prasugrel has higher bleeding risk than other
P2Y12 Inhibitor
s)
Age >75 years
Body weight <60 kg
Mechanism
See
Platelet ADP Receptor Antagonist
Bind
Platelet
ADP receptor irreversibly
Dosing
Tablet must be taken whole (do not break)
Impending
Percutaneous Coronary Intervention
(PCI)
Prasugrel 60 mg orally once
Then initiate standard 10 mg daily oral Prasugrel dose after PCI
Maintenance in coronary stenting thrombosis prevention
Prasugrel 10 mg orally once daily
Consider 5 mg oral daily if weight <60 kg
Efficacy
More effective than
Clopidogrel
in cardiovascular event reduction
Adverse Effects
Bleeding Risk
Higher risk of bleeding than
Clopidogrel
in age >75 years, weight <60 kg, CVA history
Avoid in prior
Cerebrovascular Accident
(CVA) or
Transient Ischemic Attack
(TIA)
Typically initiated in the catheter lab
Do not initiate in emergency department due to bleeding risk
Safety
Unknown safety in pregnancy
Unknown safety in
Lactation
Drug Interactions
See
Platelet ADP Receptor Antagonist
Other antiplatelet agents or
Anticoagulant
s
Agents that reduce Prasugrel activity
Opioid
s (may reduce absorption of Prasugrel)
Management
Reversal
See
Platelet ADP Receptor Antagonist
Stop 7 days before elective surgery
Resources
Prasugrel (DailyMed)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=406cc201-89b6-43cc-9e14-a59327a5b4d8
References
Filler and Lovecchio (2017) Crit Dec Emerg Med 31(7): 24
Switaj (2017) Am Fam Physician 95(4): 232-40 [PubMed]
Wiviott (2007) N Engl J Med 357(20):2001-15 [PubMed]
Type your search phrase here